Financial Performance - The company reported a net profit attributable to shareholders of -54.2964 million yuan in 2021, a significant decline of 357.27% year-on-year, primarily due to substantial goodwill impairment and increased operating expenses [6]. - The company's operating revenue for 2021 was ¥1,542,429,056.82, representing a 64.84% increase compared to ¥935,696,717.93 in 2020 [25]. - The net profit attributable to shareholders was -¥54,296,434.85 in 2021, a decrease of 357.27% from ¥21,105,083.14 in 2020 [25]. - The net cash flow from operating activities was -¥503,828,082.07, down 462.83% from ¥138,859,567.05 in 2020 [25]. - The company reported a basic earnings per share of -¥0.11 for 2021, a decline of 320.00% from ¥0.05 in 2020 [25]. - The profit distribution plan for 2021 includes no cash dividends or bonus shares, with no capital reserve conversion to shares [10]. - The company reported a net profit excluding non-recurring items of CNY -68.68 million, down 90.34% year-on-year [110]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 20% [71]. - The company reported a significant increase in revenue, achieving a total of 2,917,410,000 CNY for the year 2021 [92]. Market Position and Strategy - The company plans to continue enhancing its industry position, competitive capabilities, and sustainable development to improve operational performance [6]. - The company aims to transition from a single analysis instrument supplier to a comprehensive service provider in analysis detection through acquisitions and product diversification [58]. - The company is exploring potential mergers and acquisitions to enhance its market position and expand its product offerings [74]. - The company is focusing on expanding its market presence through strategic partnerships and collaborations, particularly in the biomedical sector [82]. - The company is committed to enhancing its technical consulting services in the medical and environmental sectors [145]. - The company is focusing on the development and sales of environmental monitoring instruments, which is a key area of growth [145]. - The company is actively involved in the research and development of medical equipment and environmental monitoring technologies [145]. Research and Development - The company has invested significantly in R&D and product line expansion, maintaining its leadership position in the domestic analysis instrument sector [69]. - The company has invested 100 million RMB in R&D for new technologies, focusing on advanced spectrometry solutions [71]. - Research and development expenses accounted for 8% of total revenue, reflecting the company's commitment to innovation [75]. - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new technologies and products in the upcoming year [74]. - The company has developed multiple new products, including various X-ray fluorescence analysis systems and software [87]. - The company has focused on enhancing its technological capabilities, with multiple software releases aimed at improving air quality monitoring and analysis [93]. Subsidiaries and Acquisitions - The company's subsidiary, Tianrui Environment, has extensive experience in environmental protection, providing services such as industrial wastewater and air treatment engineering, and has formed a closed-loop service system from monitoring to remediation [44]. - The company’s subsidiary, Bexi Bio, focuses on POCT cardiovascular testing products, enhancing its competitiveness through increased R&D investment and expanding its product range [45]. - The company has successfully completed two acquisitions in the past year, enhancing its product portfolio and market reach [91]. - The company acquired 51% of Jiangsu Guoce Testing Technology Co., Ltd. using over-raised funds amounting to 43.71 million RMB, completed on December 22, 2016 [169]. - The company purchased 55.42% of Shanghai Panhua Scientific Instrument Co., Ltd. for 168.82 million RMB, with the acquisition completed on July 27, 2017 [170]. Risks and Challenges - The company faces risks from intensified market competition, particularly from international firms like Thermo Fisher and Shimadzu, which may lead to reduced market share and lower gross margins [8]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the audit report [25]. - The company faces market competition risks from international giants and low-end product homogenization, which affects overall industry profitability [186]. - There is a risk of goodwill impairment from acquired companies if their future operating conditions deteriorate, potentially reducing current profits [188]. - The company faces risks related to talent and technology loss, which could negatively impact operations if key personnel leave or if there is a leak of technical secrets [187]. Environmental and Regulatory Factors - The company is actively exploring business opportunities in ecological protection and environmental governance, but the PPP model poses operational risks due to high investment and long cooperation periods [9]. - The implementation of the revised "Science and Technology Progress Law" in December 2021 aims to protect the market position of domestic instruments, promoting their development [47]. - The government’s "14th Five-Year Plan" emphasizes the importance of environmental quality improvement, which is expected to accelerate market demand for environmental monitoring instruments [52]. - The company is committed to sustainability, with initiatives aimed at reducing carbon emissions by 30% over the next five years [81]. Product Development and Innovation - The company has developed a comprehensive procurement system, including negotiation, competitive procurement, and inquiry-based procurement methods to ensure material quality [65]. - The company has launched new products, including a gas chromatography mass spectrometer (GC-MS 6800S) and a high-precision gear transmission automatic switching device [78]. - New product development includes the launch of a high-resolution semiconductor radiation detector, which is expected to enhance market competitiveness [72]. - The introduction of new products such as the fully automatic drug residue detection instrument and pesticide residue detection instrument is expected to drive future growth [82]. - The company has successfully obtained multiple patents, including a new coronavirus testing reagent card and a mobile emergency nucleic acid testing vehicle, enhancing its product portfolio [82]. Financial Management and Investments - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective decision-making and protection of shareholder rights [192]. - The company reported a total investment of 18,000,000,000 with a 100% ownership stake [143]. - The company has not encountered significant changes in the feasibility of its projects, ensuring ongoing alignment with strategic goals [154]. - The company has effectively utilized existing technical platforms to reduce costs in the headquarters service management center upgrade project [156]. - The company has not sold any significant assets or equity during the reporting period [160][161].

Financial Performance - The company's revenue for Q1 2023 was ¥150,599,832.55, a decrease of 23.33% compared to ¥196,426,783.79 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥2,590,555.54, representing a decline of 127.41% from a profit of ¥9,451,237.79 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.0101, a decrease of 153.16% from ¥0.019 in the same period last year[5] - Net profit for Q1 2023 was a loss of CNY 4,980,132.24, compared to a profit of CNY 9,361,839.69 in the same period last year[24] - Total operating revenue for Q1 2023 was CNY 150,599,832.55, a decrease from CNY 196,426,783.79 in the previous period[23] - Total operating costs for Q1 2023 were CNY 155,356,912.19, down from CNY 189,185,117.31 year-over-year[23] Cash Flow - The net cash flow from operating activities was -¥80,450,899.47, a decrease of 47.72% compared to -¥54,461,417.24 in the same period last year[5] - The cash inflow from operating activities totaled ¥270,522,513.80, an increase of 2.7% compared to ¥262,802,580.34 in the previous period[28] - The company's total cash outflow for operating activities was ¥350,973,413.27, compared to ¥317,263,997.58 in the previous period, indicating a 10.6% increase[28] - The company reported a decrease in cash received from other operating activities, totaling ¥6,437,255.22, down from ¥18,833,308.21[28] - Cash outflow for purchasing goods and services was ¥217,371,294.83, up from ¥176,034,123.65, reflecting a 23.5% increase[28] - The ending balance of cash and cash equivalents was ¥368,015,352.15, up from ¥297,891,372.25 in the prior period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,696,378,176.64, down 2.54% from ¥3,792,613,192.61 at the end of the previous year[5] - Current assets decreased to CNY 3,088,110,584.29 from CNY 3,189,532,183.15, reflecting a decline of approximately 3.2%[19] - Cash and cash equivalents decreased to CNY 368,015,352.15 from CNY 410,153,060.81, a reduction of about 10.3%[18] - Accounts receivable decreased to CNY 344,748,193.77 from CNY 448,441,523.37, representing a decline of approximately 23.1%[19] - The total liabilities as of March 31, 2023, were not explicitly stated but included short-term borrowings of CNY 312,360,904.32, which remained relatively stable compared to CNY 312,060,079.61 at the beginning of the year[19] - The company's total liabilities decreased to CNY 2,138,954,509.58 from CNY 2,230,448,163.42[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,475, with the largest shareholder holding 21.50% of the shares[12] - The company reported a total of 95,271,942 shares under lock-up agreements for executives, indicating a commitment to long-term stability[16] - The total equity attributable to shareholders of the parent company was CNY 1,509,563,260.06, slightly down from CNY 1,511,915,045.49[21] Investment and Development - Investment income increased by 198.67% to ¥300,712.33, primarily due to higher financial management returns[9] - The company reported a net cash outflow from investing activities of -¥69,338,720.37, an improvement of 13,340,432.35 compared to the previous year[10] - The company has a long-term investment of CNY 81,290,616.52, which increased from CNY 78,890,616.52 at the beginning of the year, reflecting a growth of approximately 3.0%[19] - The company’s development expenditure increased to CNY 9,160,842.67 from CNY 6,767,420.45, marking an increase of about 35.0%[19] - The company’s goodwill remained stable at CNY 178,692,839.97, indicating no impairment or changes during the quarter[19] Future Outlook - Future outlook includes potential strategies for market expansion and new product development, although specific details were not disclosed in the report[24]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 江苏天瑞仪器股份有限公司（以下简称"公司"）定于 2023 年 5 月 10 日（星 期三）15:00-16:30 在全景网举办 2022 年度业绩说明会，本次年度业绩说明会 将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 证券代码：300165 证券简称：天瑞仪器 公告编号：2023－029 江苏天瑞仪器股份有限公司 关于举行 2022 年度网上业绩说明会的公告 （问题征集专题页面二维码，扫码自动匹配移动端） 特此公告。 江苏天瑞仪器股份有限公司董事会 二○二三年四月二十七日 出席本次说明会的人员有：公司董事长刘召贵先生、财务总监吴志进先生、 独立董事莫卫民先生、董事会秘书朱蓉女士、保荐代表人许寅先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 10 日（星期三）15：00 前访问 https://ir.p5w ...

Financial Performance - The company's revenue for Q3 2022 was ¥155,144,733.35, a decrease of 24.82% compared to the same period last year[4] - The net profit attributable to shareholders was -¥35,382,870.93, representing a decline of 229.10% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥36,549,891.35, down 129.18% from the previous year[4] - Total operating revenue for the current period was CNY 528,322,707.98, a decrease of 13.4% compared to CNY 611,846,115.79 in the previous period[29] - Net profit for the current period was CNY -66,671,622.16, a significant decline from CNY 5,064,063.70 in the previous period, with a loss attributable to shareholders of CNY -61,784,418.74[31][32] - Basic and diluted earnings per share were both CNY -0.1243, compared to CNY 0.0083 in the previous period[32] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,447,231,568.68, an increase of 6.34% compared to the end of the previous year[4] - The company's total liabilities increased to CNY 1,845,284,363.40 from CNY 1,573,968,545.44, indicating a rise in financial obligations[30] - Non-current liabilities rose significantly to CNY 1,020,913,466.12 from CNY 460,713,636.63, primarily due to an increase in long-term borrowings[30] - Shareholders' equity attributable to the parent company decreased to CNY 1,551,772,176.24 from CNY 1,612,804,238.79, reflecting a decline in retained earnings[30] - The total assets of the company reached CNY 3,447,231,568.68, compared to CNY 3,241,835,016.69 in the previous period, indicating growth in asset base[30] Cash Flow - The cash flow from operating activities showed a net outflow of -¥120,835,185.11, which is a 56.40% improvement compared to the same period last year[4] - The net cash flow from operating activities was -120,835,185.11 CNY, an improvement from -277,162,184.18 CNY in the previous year[34] - Cash inflow from operating activities totaled CNY 927,614,788.48, an increase from CNY 789,102,835.01 in the previous period[32] - The net cash flow from financing activities was ¥51,086.02 million, an increase of 14.57% year-on-year[12] - The net cash flow from financing activities was 510,860,242.56 CNY, an increase from 445,900,695.80 CNY year-over-year[34] Shareholder Information - Total number of common shareholders at the end of the reporting period is 37,903[14] - Liu Zhaogui holds 22.56% of shares, totaling 112,116,306 shares, with 87,326,306 shares under lock-up[14] - The second largest shareholder, a fund management company, holds 5.63% with 28,000,000 shares[14] - The company has a total of 87,326,306 locked shares for Liu Zhaogui, which cannot exceed 25% of his total shares during his tenure[17] - The company reported that 0 shares were released from lock-up during the current period for Liu Zhaogui and Ying Gang[17] Investment and Expenses - The company reported a significant increase in financial expenses, totaling ¥2,039.41 million, up 287.10% due to increased bank borrowings for project financing[11] - Investment income increased to ¥353.53 million, a rise of 703.18% compared to the previous year, attributed to higher returns from equity method investments[11] - The company reported a decrease in income tax expenses to ¥228.31 million, down 70.59% due to reduced profits in the reporting period[11] - Total cash inflow from investment activities was 105,647,951.82 CNY, down from 265,375,131.59 CNY year-over-year[34] - Cash outflow for investment activities totaled 392,952,470.62 CNY, compared to 509,620,687.28 CNY in the same period last year[34]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥373.18 million, a decrease of 7.97% compared to ¥405.48 million in the same period last year[21]. - The net profit attributable to shareholders of the listed company was a loss of approximately ¥26.40 million, a decline of 277.39% compared to a profit of ¥14.88 million in the previous year[21]. - The basic and diluted earnings per share were both -¥0.05, a decrease of 266.67% compared to ¥0.03 in the same period last year[21]. - The net profit after deducting non-recurring gains and losses was a loss of approximately ¥27.60 million, a decline of 295.14% compared to ¥14.15 million in the previous year[21]. - The total comprehensive income for the first half of 2022 was a loss of CNY 30.84 million, compared to a gain of CNY 13.72 million in the previous year[193]. - The company's operating profit turned negative at CNY -26.03 million, down from a profit of CNY 20.36 million in the previous year[192]. - The company reported a total loss of CNY 2,037,967.12 from its subsidiary in Qingshui, indicating the need for strategic adjustments in this area[96]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 37.87%, amounting to a loss of approximately ¥164.66 million, compared to a loss of ¥265.03 million in the same period last year[21]. - The net cash flow from financing activities increased by 55.85%, reaching ¥438.02 million compared to ¥280.11 million in the previous year[53]. - Operating cash inflow for the first half of 2022 was CNY 556,797,594.43, an increase of 12.2% compared to CNY 496,142,165.88 in the first half of 2021[198]. - The total cash and cash equivalents at the end of the period increased to CNY 451,656,233.14 from CNY 269,467,155.97, marking a recovery in liquidity[200]. - Cash received from sales of goods and services rose to CNY 469,254,302.12, up from CNY 376,207,487.96, indicating strong revenue growth[198]. Assets and Liabilities - Total assets increased by 12.25% to approximately ¥3.64 billion, up from ¥3.24 billion at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 1.61% to approximately ¥1.59 billion from ¥1.61 billion at the end of the previous year[21]. - Long-term borrowings increased by 98.35% year-over-year to approximately ¥859.13 million, reflecting financing for ongoing projects[60]. - Total liabilities increased to CNY 2,001,327,083.17, up from CNY 1,573,968,545.44, representing a growth of approximately 27%[183]. Research and Development - Research and development investment decreased by 10.93% to ¥34.50 million from ¥38.73 million in the previous year[53]. - The company emphasizes independent innovation and has accumulated substantial technical strength in analytical instruments, aiming to maintain its leadership position in the industry[38]. - The company has established a competitive advantage in the analytical instrument market through strong R&D capabilities and a comprehensive product line[29]. Market Position and Strategy - The company is a leader in the domestic analytical instrument industry, focusing on analysis and testing, environmental monitoring, and ecological governance, with a strong emphasis on R&D capabilities[28]. - The company operates under a direct sales model as its primary sales strategy, supplemented by a distribution model for broader market reach[37]. - The company is positioned to benefit from the trend of domestic substitution in the high-end analytical instrument market, as reliance on imports decreases[38]. - The company is focusing on expanding its market presence in environmental protection equipment and services, particularly in wastewater treatment and solid waste management[96]. Subsidiaries and Acquisitions - The company has completed the acquisition of Suzhou Tianrui Environmental Technology Co., Ltd. for ¥9,725.06 million, achieving 84.09% of the expected investment[77]. - The company’s subsidiary, Tianrui Environment, has established a closed-loop service system in environmental protection, covering monitoring, diagnosis, treatment, and maintenance[46]. - The company has established a subsidiary in Hubei with an investment of 19 million CNY to focus on environmental product development and consulting[103]. Risks and Challenges - The company faces operational risks from the PPP business model due to large investment amounts and long cooperation periods, which may affect profitability[113]. - The company emphasizes the importance of innovation and aims to enhance its core competitiveness to address market competition risks[111]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[119]. Shareholder Information - The company’s total share capital is 496,990,870 shares, with 77.57% being unrestricted shares[161]. - Liu Zhaogui holds 23.41% of the shares, totaling 116,326,306 shares, with 29,000,000 shares under sale conditions[167]. - The largest shareholder, Liu Zhaogui, has not changed his holdings during the reporting period[167].

Financial Performance - Revenue for Q1 2022 was CNY 196,426,783.79, a decrease of 6.20% compared to CNY 209,411,764.69 in the same period last year[3] - Net profit attributable to shareholders was CNY 9,451,237.79, down 38.42% from CNY 15,347,795.32 year-on-year[3] - Total operating revenue for Q1 2022 was CNY 196.43 million, a decrease of 6.4% compared to CNY 209.41 million in Q1 2021[20] - Net profit for Q1 2022 was CNY 9.36 million, a decline of 38.5% from CNY 15.22 million in Q1 2021[21] - Earnings per share for Q1 2022 was CNY 0.019, compared to CNY 0.0309 in Q1 2021[22] Cash Flow - Net cash flow from operating activities was negative CNY 54,461,417.24, a decline of 132.30% compared to negative CNY 23,443,996.87 in the previous year[3] - The net cash flow from operating activities was -54,461,417.24 CNY, compared to -23,443,996.87 CNY in the previous year, indicating a decline in operational performance[25] - Total cash inflow from financing activities was 111,026,521.46 CNY, down from 227,993,529.57 CNY year-over-year, reflecting reduced financing activities[26] - The total cash and cash equivalents at the end of the period were 297,891,372.25 CNY, a decrease from 438,516,403.86 CNY in the previous year[26] - The cash outflow from investing activities was 118,006,712.24 CNY, significantly lower than 257,218,608.36 CNY in the same period last year, indicating a reduction in investment expenditures[25] Assets and Liabilities - Total assets increased by 5.00% to CNY 3,404,074,535.12 from CNY 3,241,835,016.69 at the end of the previous year[3] - Total assets as of Q1 2022 amounted to CNY 3.40 billion, an increase from CNY 3.24 billion in the previous year[18] - Total liabilities reached CNY 1.73 billion in Q1 2022, up from CNY 1.57 billion in Q1 2021[18] - Long-term borrowings increased to CNY 524.33 million in Q1 2022, compared to CNY 433.14 million in the same period last year[18] Operational Costs - Total operating costs for Q1 2022 were CNY 189.19 million, down 1.5% from CNY 192.75 million in the same period last year[20] - The company paid 62,517,952.61 CNY to employees, up from 55,062,734.29 CNY, indicating increased labor costs[25] - The cash outflow for purchasing goods and services was 176,034,123.65 CNY, compared to 160,938,109.72 CNY in the previous year, reflecting higher operational costs[25] Investments - Investment income dropped by 69.32% to CNY 100,684.93, primarily due to reduced returns from capital-protected financial products[6] - Cash outflows from investment activities decreased by 54.12% to CNY 118,006,712.24, reflecting reduced fixed asset and external investments[7] - The cash inflow from investment activities was 35,327,559.52 CNY, compared to 34,871,335.35 CNY in the previous year, showing a slight increase[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 49,561, with the largest shareholder holding 23.41% of the shares[8] - The company reported a total of 111,543,406 restricted shares at the end of the period, with 81,577 shares newly restricted[13] Miscellaneous - The company received government subsidies amounting to CNY 677,923.10 during the reporting period[5] - The company is focused on maintaining a stable financial position while exploring new market opportunities and product developments[16] - The company did not conduct an audit for the first quarter report[27]

Financial Performance - The company reported a net profit attributable to shareholders of -74.435 million yuan in 2021, a significant decline of 452.69% year-on-year, primarily due to substantial goodwill impairment and increased operating expenses [4]. - The company's operating revenue for 2021 was ¥958,340,608.40, representing a 2.42% increase compared to ¥935,696,717.93 in 2020 [26]. - The net profit attributable to shareholders in 2021 was -¥74,435,026.16, a decrease of 452.69% from ¥21,105,083.14 in 2020 [26]. - The net cash flow from operating activities was -¥503,828,082.07 in 2021, down 462.83% from ¥138,859,567.05 in 2020 [26]. - The total assets at the end of 2021 were ¥3,241,835,016.69, an increase of 26.41% from ¥2,564,439,469.59 at the end of 2020 [26]. - The company reported a basic earnings per share of -¥0.15 in 2021, a decline of 400.00% from ¥0.05 in 2020 [26]. - The total non-operating income for 2021 was ¥14,386,727.25, significantly lower than ¥57,189,568.40 in 2020 [32]. - The company experienced a quarterly revenue of ¥346,494,492.61 in Q4 2021, which was the highest among the four quarters [29]. - The net profit attributable to shareholders in Q1 2021 was ¥15,347,795.32, but turned negative in subsequent quarters, culminating in -¥78,567,185.46 in Q4 [29]. - The company's total liabilities increased, leading to a decrease in net assets attributable to shareholders by 4.70% to ¥1,612,804,238.79 at the end of 2021 [26]. - The company has indicated uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years [26]. Market Position and Competition - The company faces risks from intensified market competition, particularly from international firms like Thermo Fisher and Shimadzu, which may lead to reduced market share and lower gross margins [7]. - The company plans to continue enhancing its industry position and business competitiveness to improve operational performance despite the challenges faced [4]. - The company has formed stable partnerships with numerous well-known enterprises, enhancing its market competitiveness through collaborative synergies [44]. - The environmental protection industry is experiencing rapid growth due to increased government investment and policy support, positioning the company favorably within this sector [39]. - The company is a leader in the domestic analytical instrument industry, focusing on analysis detection, environmental monitoring, ecological governance, and related services [59]. Research and Development - The company is committed to advancing its research and development capabilities to maintain a competitive edge in the analytical instrument market [60]. - The company has established a rigorous R&D process divided into four stages: concept initiation, planned development, prototype validation, and product launch [64]. - The company has invested 30 million RMB in R&D for new technologies in environmental monitoring and analysis [72]. - The company is investing 100 million yuan in R&D for the next fiscal year to enhance product capabilities and technological advancements [75]. - The company has outlined a strategic goal to achieve a 30% increase in net profit for the next fiscal year [76]. - The company has successfully obtained 163 patents, including 45 invention patents and 118 utility model patents, enhancing its competitive edge in the market [77]. - The company has developed multiple software applications for its products, including the "VOCs Online Monitoring System Application Software V4.0," which was launched on October 15, 2017 [88]. - The company is focusing on research and development of innovative technologies to improve testing accuracy and efficiency, which is anticipated to strengthen its competitive position [83]. Product Development and Innovation - New product launches include the EDX3500 and EDX8800 spectrometers, which are expected to contribute an additional 10% to the annual revenue [73]. - The introduction of a new line of food safety testing instruments is set to launch in Q2 2022, targeting a market size of 500 million yuan [75]. - The company has introduced a new automatic monitoring system for water quality, expected to capture a significant share of the environmental monitoring market [81]. - The company is actively developing new technologies, with 15 patents granted in 2021, including innovations in X-ray fluorescence and gas chromatography [75]. - The company has developed a dual optical path colorimetric technology that significantly improves measurement stability by eliminating deviations caused by changes in light source intensity or background [98]. - The introduction of a non-contact optical quantitative sensor has reduced the cost of online water quality analyzers while ensuring sample accuracy [98]. - The company has implemented high-speed mass spectrometry data acquisition technology, significantly improving the performance metrics of mass spectrometers [98]. Strategic Acquisitions and Partnerships - The company is exploring potential acquisitions to enhance its technology portfolio and expand its capabilities in analytical instrumentation [72]. - A strategic acquisition of a smaller competitor is anticipated to be completed by Q3 2022, expected to increase market share by 5% [74]. - The company has completed the acquisition of 100% equity in Suzhou Wending Environmental Technology Co., Ltd. for 135 million, integrating it as a wholly-owned subsidiary [165]. - The company is focused on expanding its market presence through strategic acquisitions and establishing new subsidiaries in the environmental technology sector [164]. - The company has established a new subsidiary in Hunan with an investment of 10 million yuan to develop medical devices and related technologies [172]. Financial Management and Investment - The company has a procurement model that includes long-term partnerships with several well-known suppliers for core components and key raw materials, ensuring quality and cost-effectiveness [65]. - The cash inflow from financing activities increased by 63.50% to ¥862,032,594.39, mainly due to increased bank loans [126]. - The company reported a significant increase in financial expenses by 95.31% year-over-year, totaling approximately ¥22.54 million, attributed to increased bank loans for project financing [119]. - The company has a cash balance of CNY 21.90 million, which is restricted due to performance guarantees and bank account freezes [136]. - The company has pledged 99% of its equity in a subsidiary as collateral for a bank loan amounting to CNY 99 million [136]. Operational Challenges and Risks - The company has indicated uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years [26]. - The company faces risks from market competition, particularly from international giants and low-end product homogenization, which affects overall industry profitability [181]. - There is a risk of talent and technology loss, which could negatively impact production and operations if key personnel leave [182]. - The company aims to minimize the impact of goodwill from acquisitions on future performance by optimizing resource allocation and maintaining competitive advantages across business segments [183]. Corporate Governance - The company held five shareholder meetings during the reporting period, all conducted in compliance with regulations, ensuring the legality and effectiveness of voting results [188]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirements of relevant laws and regulations [190]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal standards [192]. - The company maintains an independent business operation, with no competition or unfair related transactions with the controlling shareholder [196]. - The company has a complete governance structure that complies with the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange [195].

Financial Performance - The company's revenue for Q3 2021 was ¥206,366,073.04, a decrease of 12.42% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥10,751,321.07, representing a decline of 126.01% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥15,948,128.89, a significant decrease of 4,531.02% compared to the previous year[3]. - The basic earnings per share for Q3 2021 was -¥0.0216, down 124.17% year-on-year[3]. - The weighted average return on net assets was -0.63%, a decrease of 3.17% compared to the previous year[3]. - The company reported a net profit of CNY 5.06 million for Q3 2021, a decrease of 66.67% compared to CNY 15.12 million in Q3 2020[26]. - The net profit for Q3 2021 was CNY 5,064,063.70, a decrease from CNY 19,600,254.19 in the same period last year, representing a decline of approximately 74.1%[27]. - The net profit attributable to the parent company was CNY 4,132,159.30, down from CNY 22,751,988.84, indicating a decrease of about 81.8% year-over-year[27]. - The basic and diluted earnings per share for the current period were CNY 0.0083, compared to CNY 0.0493 in the previous year, reflecting a decline of approximately 83.2%[27]. Cash Flow - The operating cash flow net amount for the year-to-date was -¥277,162,184.18, an increase of 349.19% compared to the same period last year[3]. - Net cash flow from operating activities decreased by 349.19% to -¥27,716.22 million, attributed to increased procurement for PPP projects and related payments[11]. - Cash inflows from operating activities totaled CNY 789,102,835.01, an increase from CNY 711,837,010.37 in the previous year, marking a growth of about 10.8%[29]. - Cash outflows from operating activities amounted to CNY 1,066,265,019.19, compared to CNY 773,540,070.76 in the same period last year, representing an increase of approximately 37.9%[29]. - The net cash flow from operating activities was negative at CNY -277,162,184.18, worsening from CNY -61,703,060.39 in the previous year[29]. - The total cash inflow from investing activities was CNY 265,375,131.59, up from CNY 184,545,351.49, indicating an increase of about 43.8% year-over-year[30]. - The net cash flow from investing activities was negative at CNY -244,245,555.69, compared to CNY -124,470,248.46 in the previous year, reflecting a decline of approximately 96.1%[30]. - The net cash flow from financing activities was CNY 445,900,695.80, significantly higher than CNY 122,873,160.57 in the previous year, showing an increase of about 263.5%[30]. - The ending cash and cash equivalents balance was CNY 379,674,778.16, compared to CNY 276,310,371.77 at the end of the same period last year, representing an increase of approximately 37.4%[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,259,158,575.06, reflecting a growth of 27.09% from the end of the previous year[3]. - Total current assets as of September 30, 2021, amounted to CNY 1.64 billion, an increase of 10.27% from CNY 1.49 billion at the end of 2020[23]. - Total liabilities increased to CNY 1.52 billion, a significant rise of 83.96% from CNY 825.38 million at the end of 2020[24]. - Current liabilities totaled CNY 765,376,459.20, with a minor decrease of CNY 404,887.73[34]. - The company's equity attributable to shareholders was CNY 1,692,340,284.79, showing a decrease of CNY 482,930.39[35]. - The company reported a long-term investment of CNY 54,576,348.36, unchanged from the previous period[33]. Investments and Expenses - R&D expenses increased by 37.55% to ¥5,536.75 million due to the addition of new research projects[11]. - Research and development expenses increased to CNY 55.37 million, a rise of 37.59% compared to CNY 40.25 million in Q3 2020[26]. - Long-term borrowings surged by 763.04% to ¥43,236.00 million primarily for the construction of the Yaan urban sewage treatment facility PPP project[11]. - Investment income turned negative at -¥58.61 million, a decline of 138.48% compared to the previous period due to increased investment losses[11]. - Total operating costs for Q3 2021 were CNY 609.88 million, up from CNY 539.14 million in the same period last year, reflecting a growth of 13.06%[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,884[14]. - As of September 30, 2021, the total number of restricted shares was 202,211,509, with 31,105,448 shares released during the period[19]. - The company reported a total of 171,106,061 restricted shares remaining at the end of the period[19]. - The company has a total of 4,539,195 shares that are restricted due to fundraising for asset acquisition[18]. - The company has 13,634,389 shares restricted for fundraising related to asset acquisition, with a 12-month lock-up period[18]. Regulatory and Compliance - The report for the third quarter was not audited[36]. - The company decided to terminate the issuance of shares to specific targets and withdrew the application documents on July 7, 2021[20]. - The full subsidiary, Henan Tianrui Environmental Technology Co., Ltd., changed its business scope to include resource recycling services and environmental consulting[20]. - The company has implemented a new leasing standard effective from January 1, 2021, impacting the recognition of right-of-use assets and lease liabilities[35].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥405,480,042.75, representing a 32.48% increase compared to ¥306,057,731.95 in the same period last year[22]. - The net profit attributable to shareholders of the listed company reached ¥14,883,480.37, a significant turnaround from a loss of ¥18,577,151.11 in the previous year, marking an increase of 180.12%[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥14,145,665.44, compared to a loss of ¥28,403,167.35 last year, reflecting a 149.80% improvement[22]. - The basic earnings per share were ¥0.0299, a recovery from a loss of ¥0.0402 per share in the same period last year, indicating a 174.38% increase[22]. - The total comprehensive income attributable to the parent company was CNY 14,883,480.37, compared to a loss of CNY 18,577,151.11 in the first half of 2020[179]. - The company reported a net profit of 149,454,384 CNY, reflecting a strong performance in its core business segments[75]. - The company reported a net loss of CNY 9,234,000 for the first half of 2021[192]. - The total comprehensive income for the period was reported at 7,151 million yuan, which is a decrease of 18.57% from the previous year[191]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,916,356,802.10, up 13.72% from ¥2,564,439,469.59 at the end of the previous year[22]. - The company's total assets as of June 30, 2021, amounted to CNY 2,916,356,802.10, an increase from CNY 2,564,439,469.59 at the end of 2020[165]. - The total liabilities rose to CNY 1,168,502,607.09 from CNY 825,379,245.12, indicating an increase of around 41.7%[167]. - The company's total liabilities decreased to CNY 539,596,312.17 from CNY 548,012,527.16 at the end of 2020, indicating improved financial stability[172]. - The total equity attributable to shareholders increased to CNY 1,939,880,228.87 from CNY 1,910,578,900.70 at the end of 2020, reflecting positive retained earnings[172]. Cash Flow - The net cash flow from operating activities was negative at -¥265,031,778.65, worsening from -¥91,269,185.74 in the same period last year, reflecting a decline of 190.38%[22]. - The company reported a significant decline in cash flow from operating activities, with a net outflow of ¥265,031,778.65, a decrease of 190.38% year-on-year, attributed to increased procurement for PPP projects[37]. - The company reported a net cash outflow from operating activities of CNY -265,031,778.65, worsening from CNY -91,269,185.74 in the first half of 2020[182]. - Cash and cash equivalents at the end of the first half of 2021 were CNY 269,467,155.97, down from CNY 455,222,662.28 at the beginning of the period[183]. Research and Development - Research and development expenses increased by 39.53% to ¥38,730,590.33, mainly due to an increase in R&D projects[37]. - The company has a strong R&D capability, continuously enriching its product range and expanding into new application areas[29]. - The company is focusing on the development of new technologies in wastewater treatment, with investments amounting to 20,000,000 CNY in related R&D activities[76]. - The company emphasized the importance of R&D investment to enhance core competitiveness and expand product lines in environmental monitoring, food safety, and medical testing[87]. Market and Business Strategy - The company plans to continue expanding its R&D efforts and is focusing on enhancing its product offerings in the environmental monitoring sector[37]. - The company plans to expand its market presence through the establishment of new subsidiaries, including Tianlan Xiangrui and Hunan Beixi, which are expected to contribute positively to future earnings[77]. - The company is actively pursuing mergers and acquisitions to strengthen its market position, having previously acquired 100% of Shanghai Beixi Biotechnology Co., Ltd. for 36,000,000 CNY[79]. - The company is committed to enhancing its service offerings in environmental monitoring and consulting, which are expected to drive future revenue streams[77]. Risks and Compliance - The management has highlighted potential risks and corresponding measures in the report, which investors are advised to review carefully[4]. - The company faced risks from intensified market competition and potential declines in gross margins due to price competition with foreign manufacturers[86]. - The company maintains compliance with national laws and regulations, focusing on both economic and social benefits[98]. - The company has not reported any significant mergers or acquisitions during this period, focusing instead on organic growth strategies[189]. Shareholder Information - The company completed a non-public issuance of 6,805,040 shares on January 12, 2021, increasing the total share capital from 490,185,830 to 496,990,870[128]. - The total number of ordinary shareholders at the end of the reporting period was 22,859[148]. - Liu Zhaogui, a major shareholder, holds 29.04% of the shares, totaling 4,326,306 shares, with a decrease of 9,939,817 shares during the reporting period[149]. - The company has not reported any strategic investors or general legal entities becoming top ten shareholders due to new share subscriptions[149]. Legal Matters - The company reported a total of 3,000,000 yuan involved in a lawsuit with Shenzhen Kangmei Biological Technology Co., Ltd., which is currently in the second instance of trial[107]. - Another lawsuit with Jiangxi Maiwang Environmental Technology Co., Ltd. involves 628,000 yuan and is awaiting further court hearings[107]. - The company has not faced any major litigation or arbitration matters during the reporting period[106]. Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[6]. - The company did not distribute any dividends during this reporting period, maintaining a focus on reinvestment[189].

Financial Performance - The company's revenue for Q1 2021 was ¥209,411,764.69, representing a 44.67% increase compared to ¥144,755,161.80 in the same period last year[8] - Net profit attributable to shareholders decreased by 7.40% to ¥15,347,795.32 from ¥16,574,324.53 year-on-year[8] - The net profit excluding non-recurring gains and losses increased by 3.20% to ¥15,948,734.07 compared to ¥15,454,492.03 in the previous year[8] - Basic earnings per share decreased by 13.93% to ¥0.0309 from ¥0.0359 in the same period last year[8] - Diluted earnings per share also decreased by 13.93% to ¥0.0309 compared to ¥0.0359 in the previous year[8] - The weighted average return on equity was 0.90%, down from 1.03% in the same period last year[8] - Operating profit reached CNY 21.15 million, up 28.26% year-over-year[23] - Net profit attributable to the parent company was CNY 15.35 million, a decrease of 7.40% from the previous year, primarily due to increased operating and R&D expenses[23] - The company reported a total operating revenue of CNY 209.41 million, an increase of 44.67% compared to the same period last year[21] Cash Flow and Assets - The net cash flow from operating activities improved by 64.35%, reaching -¥23,443,996.87, compared to -¥65,767,787.93 in the same period last year[8] - Cash inflow from operating activities totaled CNY 298.73 million, a 61.93% increase, attributed to higher sales collections[21] - Cash outflow from operating activities was CNY 322.18 million, up 28.74%, mainly due to increased procurement costs[21] - The company reported a net cash flow from operating activities of CNY -23.44 million, an improvement of 64.35% compared to the previous year[21] - Cash flow from operating activities was CNY 282,992,682.60, compared to CNY 155,854,310.65 in the previous period, showing an increase of approximately 81.6%[66] - The company's total current assets as of March 31, 2021, amounted to CNY 1,606,850,215.56, an increase from CNY 1,486,097,288.03 on December 31, 2020, reflecting a growth of approximately 8.1%[48] - Cash and cash equivalents decreased to CNY 438,516,403.86 from CNY 462,696,662.28, representing a decline of about 5.2%[49] - The company reported a total cash outflow from investing activities of 257,218,608.36 CNY, significantly higher than 37,820,432.38 CNY in the previous period, indicating increased investment activities[67] Research and Development - R&D expenses surged to CNY 18.92 million, reflecting a 99.01% increase year-over-year, driven by the expansion of R&D projects[21] - Research and development expenses rose significantly to CNY 18,920,039.36, compared to CNY 9,507,210.62 in the same period last year, reflecting a growth of approximately 99.5%[59] - The company is in the prototype testing phase for several new products, including the GC-MS 6800 and POW-II systems, with ongoing tests expected to continue[23] - The company is in the process of clinical evaluation for various hormone test kits, including testosterone and progesterone[25] - The company has completed the engineering prototype preparation for several immunoassay kits, which are currently undergoing registration inspection[26] Shareholder and Market Activities - The total number of shares held by major shareholders is 170,776,061, with 6,805,040 shares subject to lock-up restrictions[18] - The company has a total of 75% lock-up on shares for executives during their tenure, with specific unlock schedules based on the issuance date of new shares[16] - The company is actively managing its share structure to align with strategic growth initiatives and investor confidence[20] - The company is focusing on enhancing its marketing system to increase market share, particularly in sectors like environmental protection and food safety[29] - The company is transitioning its overseas business promotion and after-sales service from offline to online platforms, adapting to current market conditions[30] Investments and Acquisitions - The company has issued shares for asset acquisitions, with a total of 13,634,389 shares involved in these transactions[18] - The acquisition of Suzhou Tianrui Environmental Technology Co., Ltd. was completed with an investment of 81.78 million, achieving 84.09% of the planned investment[38] - The acquisition of Shanghai Beixi Biological Technology Co., Ltd. was fully paid with an investment of 360 million, achieving 100% of the planned investment[38] - The company plans to use excess raised funds for various strategic investments, including loan repayment and working capital supplementation[39] Environmental and Technological Development - The company is advancing its technology development in various environmental applications, including zero discharge technology for tin-containing wastewater and modular artificial wetland systems for rural wastewater treatment[27] - The company has successfully completed projects related to soil contaminant analysis, including the determination of phthalate content and ammonia nitrogen uncertainty assessment[27] - The company has established a technical development phase for the analysis of volatile halogenated hydrocarbons in fixed pollution sources, reflecting its commitment to air quality monitoring[27] Risks and Challenges - The company faces risks from intensified market competition and potential declines in gross margins due to price competition with foreign manufacturers[32] - The company emphasizes continuous investment in R&D to mitigate risks associated with new product launches not meeting expectations[32] - The company is committed to optimizing its organizational structure and enhancing human resource management to improve operational efficiency[30]